【24h】

Acquired factor XIII deficiency: A review

机译:获得的因素XIII缺乏:审查

获取原文
获取原文并翻译 | 示例
           

摘要

Acquired factor XIII (FXIII) deficiency is a rare bleeding disorder that can manifest with spontaneous or delayed life-threatening hemorrhage. Causes of acquired deficiency include immune-mediated inhibition, as well as non immune FXIII hyperconsumption or hyposynthesis. The occurrence of acquired FXIII deficiency can be idiopathic or may be associated with comorbidities, such as malignancies or autoimmune disorders. Recognition of acquired FXIII deficiency and its underlying cause is imperative, as treatment options vary depending on the etiology. Diagnosis requires quantitative FXIII testing in addition to supplemental inhibitor studies if the clinical situation suggests an immune-mediated pathophysiology. Treatment may involve FXIII replacement, anti-fibrinolytic administration, and/or inhibitor eradication. However, treatment targets and thresholds are undefined in acquired FXIII deficiency. This review will focus on the clinical characteristics, diagnostic issues and therapeutic options for both immune and non-immune acquired FXIII deficiency. Cases are described to illustrate the clinical features of acquired FXIII deficiency.
机译:获得的因子XIII(FXIII)缺乏是一种罕见的出血性疾病,可用自发或延迟危及生命的出血。获得的缺乏的原因包括免疫介导的抑制,以及非免疫FXIII超催化或过量合成。获得的FXIII缺乏的发生可以是特发性的,或者可能与可恶性的合并症,例如恶性肿瘤或自身免疫障碍。认识到获得的FXIII缺乏及其潜在原因是必要的,因为治疗期权因病因而异。如果临床情况表明免疫介导的病理生理学,诊断除了补充抑制剂研究外,还需要定量的FXIII测试。治疗可能涉及FXIII替代,抗纤维蛋白溶解给药和/或抑制剂根除。然而,在获得的FXIII缺乏中未定义治疗靶标和阈值。本综述将专注于免疫和非免疫因素缺乏症的临床特征,诊断问题和治疗选择。描述了病例来说明获得的FXIII缺乏的临床特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号